Get started
Author

Michael Korn

Gastric Cancer
2010 · Jaffer A. Ajani, James S. Barthel, et al. · Journal of the National Comprehensive Cancer Network · 161
Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications
2021 · Roberto Moretto, Andrew Elliott, et al. · JNCI Journal of the National Cancer Institute · 79
PDF
Phase I study with a weekly 1 h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer
1996 · U. Klaassen, H. Wilke, et al. · European Journal of Cancer · 68
Phase II trial of FOLFOX plus bevacizumab in advanced, progressive neuroendocrine tumors
2008 · A. P. Venook, A. H. Ko, et al. · Journal of Clinical Oncology · 52
Transcriptional activation of TRADD mediates p53-independent radiation-induced apoptosis of glioma cells
2001 · Garret L Yount, Golnar Afshar, et al. · Oncogene · 30
A Phase I Dose Escalation Trial of Intravenous Treosulfan in Refractory Cancer
2009 · A. Harstrick, H. Wilke, et al. · Onkologie · 24
Phase I trial of an oral TORC1/TORC2 inhibitor (CC-223) in advanced solid and hematologic cancers.
2012 · Kent C. Shih, Johanna C. Bendell, et al. · Journal of Clinical Oncology · 20
Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?
2022 · Roberto Moretto, Andrew Elliott, et al. · British Journal of Cancer · 14
PDF
Phase II study with cisplatin and paclitaxel in combination with weekly high-dose 24 h infusional 5-fluorouracil/leucovorin for first-line treatment of metastatic breast cancer
1998 · Ute Klaassen, Hansjochen Wilke, et al. · Anti-Cancer Drugs · 14
Weekly infusional 5-fluorouracil plus/minus other drugs for the treatment of advanced gastric cancer.
1996 · H Wilke, M Korn, et al. · PubMed · 14
Pegilodecakin with nivolumab (nivo) or pembrolizumab (pembro) in patients (pts) with metastatic renal cell carcinoma (RCC).
2018 · Nizar M. Tannir, Aung Naing, et al. · Journal of Clinical Oncology · 10
Poly-Ligand Profiling differentiates pancreatic cancer patients according to treatment benefit from gemcitabine+placebo versus gemcitabine+evofosfamide and identifies candidate targets
2018 · V. Domenyuk, X. Liu, et al. · Annals of Oncology · 6
Phase II Study of Weekly High-Dose 5-Fluorouracil and Folinic Acid plus Biweekly Alternating Cisplatin and Epirubicin (FUFACE) in Patients with Advanced Gastric Carcinoma
2009 · M. Stahl, U. Vanhoefer, et al. · Onkologie · 6
360 Phase I/II study with paclitaxel in combination with weekly high dose 5-FU/Folinic acid in the treatment of metastatic breast cancer
1995 · U. Klaassen, H. Wilke, et al. · European Journal of Cancer · 6
Phase Ib dose-escalation trial of the AKT inhibitor (AKTi) MK2206 in combination with paclitaxel (P) and trastuzumab (H) in patients (pts) with HER2-overexpressing (HER2+) cancer.
2013 · Amy Jo Chien, Thach-Giao Truong, et al. · Journal of Clinical Oncology · 5
Infusional 5-FU, folinic acid, paclitaxel, and cisplatin for metastatic breast cancer.
1997 · U Klaassen, H Wilke, et al. · PubMed · 3
Poly-ligand profiling (PLP) to differentiate pancreatic cancer patients who benefit from gemcitabine+evofosfamide versus gemcitabine+placebo treatment.
2018 · Valeriy Domenyuk, Daniel Magee, et al. · Journal of Clinical Oncology · 2
FOXL2 mutation is prevalent in metastatic adult granulosa cell tumors and is associated with improved survival
2021 · Emily MacArthur, Alison Garrett, et al. · Gynecologic Oncology · 1
379 Frequency and molecular associations of KRAS mutations in gynecologic malignancies
2020 · K. Kilowski, M. Dietrich, et al. · International Journal of Gynecological Cancer · 1
PDF
Mp41-15 Germline Dna Damage Repair Gene Mutations in Early Stage Prostate Cancer Patients Undergoing Active Surveillance or Definitive Local Treatment
2024 · James T. Kearns, Sarah M. Nielsen, et al. · The Journal of Urology
P164: Scalable Bayesian variant interpretation of Lynch syndrome genes using genotype and phenotype data for over 1.5M patients referred for testing*
2024 · Toby Manders, Yuya Kobayashi, et al. · Genetics in Medicine Open
PDF
P073: Novel high-throughput functional models for MLH1, MSH2, and PMS2 have high accuracy for clinical variant classification
2024 · David Stafford, Jason Reuter, et al. · Genetics in Medicine Open
Molecular profiling of gestational trophoblastic neoplasia: Identifying therapeutic targets (167)
2022 · Marilyn Huang, Sharon Wu, et al. · Gynecologic Oncology
Correlation of CCNE1 copy number levels with molecular profiles and outcomes for high grade serous ovarian and endometrial cancer (121)
2022 · Erin George, Emily Ko, et al. · Gynecologic Oncology
Abstract 48: Molecular characteristics of HRAS mutated non-small cell lung cancer (NSCLC)
2022 · Asaad Trabolsi, Estelamari Rodriguez, et al. · Cancer Research
Works count: 39
Citation count: 516
H-index: 10
I10-index: 11
Year
Topic
Type